Statins may aggravate myasthenia gravis

Muscle and Nerve

Volumn 38, Issue 3, 2008, Pages 1101-1107

  Oh, Shin J ^a   Dhall, Rohit ^a   Young, Angela ^a   Morgan, Marla B ^a   Lu, Liang ^a   Claussen, Gwendolyn C ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Drug side effect; HMG coenzyme A reductase inhibitor; Myasthenia gravis; Myotoxicity; Statin

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STEROID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIPLOPIA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; MYASTHENIA GRAVIS; MYOPATHY; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES;

EID: 51349100346     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21074     Document Type: Article

References (21)

1. Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve 2006;34:478-481.
2. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-Co A reductase inhibitors (statins): a critical overview. Adv Ther 1998;15:218-228.
3. Cartwright MS, Jeffery DR, Nuss GR, Donofrio P. Statin-associated exacerbation of myasthenia gravis. Neurology 2004;63;2188.
4. Engel WK. Reversal ocular myasthenia gravis or mitochondrial myopathy from statins. Lancet 2003;361:85-86.
5. Golman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol lowering agents in drug induced rhabomyolysis and polymyositis. Arthritis Rheum 1989;32:358-359.
6. Jimenez-Alonso J, Maimez L, Sabio JM, Hidalgo C, Leon L. Atorvaslatin-induced reversible positive antinuclear antibodies. Am J Med 2002;112:329-330.
7. Negvesky GJ, Kolsky MP, Laureno R, Yau TH. Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia. Arch Ophthalmol 2000;118:427-428.
8. Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic sensitivity of laboratory tests in myasthenia gravis. Muscle Nerve 1992;15:720-724.
9. Parmar B, Francis P, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet 2002;360:717.
10. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-1028.
11. Penn AS, Low BW, Jaffe IA, Luo L, Jacques JJ. Drug-induced autoimmuine myasthenia gravis. Ann NY Acad Sci 1998;841:433-449.
12. Purvin V, Kawasaki A, Kyle H, Smith KH, Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine 2006;85:82-85.
13. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-416.
14. Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. Medicine 1998;77:378-383.
15. Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve 1994;17:891-894.
16. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006;166:1519-1524.
17. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000;22:441-457.
18. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004;30:803-807.
19. Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG. Statin-disclosed acid maltase deficiency. J Intern Med 2005;258:196-197.
20. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95-112.
21. Wittbrodt ET. Drugs and myasthenia gravis. An update. Intern Med 1997;157;399-408.